Document is current

Article History

Received: 19 August 2024

Accepted: 27 May 2025

First Online: 2 June 2025

Declarations

:

: This study protocol was reviewed and approved by the local ethics committee of the university hospital, Goethe-University, Frankfurt/Main, approval number 200–561. According to the local requirements of the University Hospital Ethics Committee, written informed consent was not required due to the retrospective nature of the study and the guaranteed anonymity of the published data.

: Not applicable.

: Patient consent was not required in accordance with local guidelines.

: Part of the results were presented as an abstract at the German DGP Congress 2021 (online).

: A. Grünewaldt reports personal fees from Boehringer Ingelheim for lectures and GSK for advisory boards. G. Rohde reports personal fees from Astra Zeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Solvay, Takeda, Novartis, Pfizer, and Vertex for consultancy during advisory board meetings, furthermore personal fees from Astra Zeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Solvay, Takeda, Novartis, Pfizer, and Vertex for lectures.